Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Clene Inc.NASDAQ: CLNN

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI rises 151.2% from a year ago

Accumulated OCI stood at $216K at the end of Q1 FY2026, up 151.2% from a year earlier and up 25.6% from the prior quarter. Over 3 fiscal years it compounded at -5.4% a year.

Context

  • Accumulated OCI amounted to 1.0% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +151.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$216K+25.6% QoQ
Last fiscal yearDec 2025
$172K+142.3% YoY
Year agoMar 2025
$86K+151.2% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+151.2%——
1 year+142.3%——
3-year CAGR-5.4%——
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
172K USD
Year-over-year change
+142.3%
4-year CAGR
-7.3%

Accumulated OCI vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's Mar 2026 Accumulated OCI of $216K is the highest of the 11 companies compared; the peer median is -$21K.
  • Its year-over-year change of +151.2% is the highest of 8, against a peer median of -314.5%.
  • Accumulated OCI amounts to 1.0% of total assets for CLNN, versus a peer median of 0.0%.
CLNN Competitors Peer median
Accumulated OCI for CLNN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CLNNClene Inc.Mar 2026$216K +151.2%-5.4%1.0%
STTKShattuck Labs, Inc.Mar 2026$0 -100.0%—0.0%
ORMPOramed Pharmaceuticals Inc.Mar 2026$0 ——0.0%
COYACoya Therapeutics, Inc.Mar 2026$0 ——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 ——0.0%
WHWKWhitehawk Therapeutics IncMar 2026-$15K -1600.0%—0.0%
MGNXMacroGenics, Inc.Mar 2026-$27K -2600.0%—0.0%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026-$50K -114.0%—0.0%
PLRXPliant Therapeutics, Inc.Mar 2026-$341K -314.5%—0.2%
OVIDOvid Therapeutics Inc.Mar 2026-$422K -779.2%—0.2%
CNTBConnect Biopharma Holdings LimitedDec 2025-$1.19M +28.5%—2.1%
Peer median (excluding CLNN) -$21K-314.5%—0.0%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents50.29M18.33M28.82M12.16M5.19M
Short-term Investments04.98M6.18M00
Net Receivables1.61M2.97M1.34M391K590K
Inventory41K43K37K68K37K
Other Current Assets2.45M2.87M2.48M137K139K
Total Current Assets54.58M29.2M38.85M16.16M8.98M
Property, Plant & Equipment (Net)8.42M15.24M13.43M11.12M9.1M
Goodwill00000
Intangible Assets00000
Long-term Investments58K58K058K58K
Tax Assets00000
Other Non-current Assets0058K00
Total Non-current Assets8.48M15.3M13.49M11.18M9.15M
Total Assets63.06M44.49M52.34M27.34M18.13M
Account Payables1.92M3.01M1.5M1.24M892K
Short-term Debt06.42M19.5M359K4.07M
Tax Payables00000
Deferred Revenue520K520K02.67M1.51M
Other Current Liabilities2.05M1.49M2.12M4.08M3.14M
Total Current Liabilities6.03M13.86M25.33M10.29M10.78M
Long-term Debt19.08M19.25M7.15M15.43M13.54M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities20.89M2.56M1.57M6.35M8.16M
Total Non-current Liabilities44.44M27.4M13.62M25.9M24.95M
Total Liabilities50.47M41.26M38.95M36.19M35.72M
Common Stock6K7K13K1K1K
Retained Earnings(163.3M)(193.22M)(242.72M)(282.12M)(308.3M)
Accumulated OCI233K203K199K71K172K
Other Stockholders Equity00000
Minority Interest00000
Total Equity12.6M3.24M13.39M(8.86M)(17.59M)
Total Debt24.04M31.82M32.16M20.84M21.67M
Net Debt(26.25M)13.49M3.34M8.69M16.48M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.